In a dramatic turn for the embattled biotech sector, Accelerate Diagnostics, Inc. has voluntarily filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware, aiming to reorganize and sell off its assets under the court’s supervision. The move places the once-promising diagnostics innovator at the center of a high-stakes restructuring saga that could reshape its future—or end it entirely.

A $12.5M Lifeline to Keep the Lights On

As part of its initial Chapter 11 filings, the Tucson, Arizona-based company submitted a slate of “first day” motions, requesting judicial approval to maintain normal business operations during the proceedings. This includes authorization to access up to $12.5 million in debtor-in-possession (DIP) financing, a crucial infusion that will allow Accelerate to pay employees, support vendors, and serve customers as the sale process unfolds.

Pending court approval, the DIP financing facility will provide the necessary fuel for the company to run its engines during what is expected to be a turbulent but controlled descent.

The Sale Strategy: A Bidding War or a Clean Exit?

In a twist that adds intrigue to the unfolding bankruptcy, Indaba Capital Management—already the majority holder of Accelerate’s secured notes—has emerged as the “stalking horse” bidder, laying the groundwork for the company’s asset sale.

The terms of Indaba’s offer include:

• A $36.9 million credit bid combining existing secured notes and DIP obligations

• Assumption of certain liabilities

• Exclusion of enough cash to cover the wind-down of remaining operations post-sale

But this deal is far from done. The bid, made under Section 363 of the Bankruptcy Code, sets the floor price for the company’s assets. The court-supervised sale process will open the door to competing bids, potentially igniting a bidding war among interested third parties. If other qualified bids emerge, Accelerate will conduct an auction. If not, Indaba walks away with the prize.

A Controlled Crash or a Strategic Reset?

This filing marks a sobering chapter for a company that once aimed to revolutionize infectious disease diagnostics. With pressures mounting from debt obligations and an increasingly unforgiving financial market, Accelerate’s leadership is banking on this Chapter 11 path as a way to stabilize operations and extract value from its assets.

“This move allows Accelerate to maintain business continuity while maximizing value for stakeholders through a structured and competitive sale process,” said a person close to the matter.

Legal and Financial Firepower in Place

To navigate the complex legal and financial terrain of Chapter 11, Accelerate has retained:

• Fried, Frank, Harris, Shriver & Jacobson LLP as legal counsel

• Solic Capital as financial advisor

• Perella Weinberg Partners L.P. as restructuring investment banker

These heavy-hitters are tasked with executing a high-wire act—preserving business value while navigating a labyrinth of creditor interests, regulatory oversight, and market skepticism.

The coming weeks will determine whether Accelerate Diagnostics survives as a streamlined version of its former self—or becomes a cautionary tale in biotech finance. With the courtroom now the battlefield, all eyes turn to Delaware as bidders, bankers, and lawyers prepare for a deal that could change the company’s fate forever.